002223 鱼跃医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,231,209-17.44%7,971,7347,101,6796,894,3086,725,687
减:营业总成本1,584,225-14.27%5,804,4265,605,8725,382,0584,887,664
    其中:营业成本1,116,937-12.61%3,866,8703,683,6433,565,2993,182,544
               财务费用(50,843)4,519.01%(157,469)(96,253)(8,638)127,900
               资产减值损失(56)-99.81%(92,980)(104,090)(20,634)(35,977)
公允价值变动收益53-99.76%(4,106)2,1602,165(322)
投资收益(855)-111.32%143,208129,132115,831127,096
    其中:对联营企业和合营企业的投资收益----11,82313,2197,80611,535
营业利润777,028-10.19%2,893,4941,841,8041,688,0472,009,669
利润总额778,194-5.96%2,848,8351,842,4181,701,8442,018,647
减:所得税费用117,168-2.69%472,362269,728217,820262,037
净利润661,025-6.52%2,376,4721,572,6901,484,0241,756,610
减:非控股权益1,612-125.26%(19,381)(22,348)1,602(2,452)
股东净利润659,413-7.58%2,395,8531,595,0371,482,4221,759,062

市场价值指针
每股收益 (元) *0.662-7.89%2.4101.6101.4901.750
每股派息 (元) *----0.8000.6000.3000.300
每股净资产 (元) *12.40217.51%11.7359.8368.2527.419
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容